{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/UNCY",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Unicycive Therapeutics, Inc. (NASDAQ: UNCY) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Unicycive Therapeutics, Inc., listed on NASDAQ under ticker UNCY. Its ISIN is US90466Y2028. Its LEI is not on the record (no GLEIF record with the exact legal name in jurisdiction US-DE). Its security type is Corporate, its segment is not on the record, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is United States, Delaware. Its listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 56 filings in the twelve months to 2026-11-08, across 30 filing days. The filings comprise 4 agm_egm, 4 corporate_news, 2 director_change, 16 directors_dealings, 2 prospectus, 20 regulatory_filing and 8 results. The median gap between filing days is 6 days. The latest filing is dated 2026-10-29 and is of type directors_dealings, 10 days before the record date. The exchange median for NASDAQ is 52 filings, a cadence gap of 6.0 days and a latency of 5.0 days across 4359 issuers. The sector median for 2834 Pharmaceutical Preparations is 63.0 filings, a cadence gap of 6.0 days and a latency of 4.0 days across 526 issuers.\n\n## Auditor\n\nThe auditor of record is GRASSI & CO., CPAs, P.C., located in Jericho, New York. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting or name change lines. The domicile change is not on the record (EDGAR states no dated change of state of incorporation on a filing line). The segment move is not on the record (the exchanges' tier transfers are not EDGAR filings). The halt flag reads listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nThe issuer's own investor-relations page names 10 research houses: B. Riley, Brookline Capital Markets, Guggenheim Securities, H.C. Wainwright, Lucid Capital Markets, Maxim Group, Noble Life Science Partners, Piper Sandler, The Benchmark Company, LLC, and WestPark Capital.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe sealed years that hold the issuer are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12. The market's vintage is sealed.\n\n## Sources\n\n9 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)\n- https://data.sec.gov/submissions/CIK0001766140.json (identity.jurisdiction)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/UNCY (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm (the auditor)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://ir.unicycive.com/financial-stock-info/analyst-coverage (coverage)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/UNCY (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm",
    "state": "sourced",
    "value": "GRASSI & CO., CPAs, P.C."
   },
   "auditor_firm_id": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm",
    "state": "sourced",
    "value": "606"
   },
   "auditor_location": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm",
    "state": "sourced",
    "value": "Jericho, New York"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/UNCY",
  "coverage": {
   "count": 10,
   "houses": [
    {
     "analyst": "Mayank Mamtani",
     "house": "B. Riley",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.unicycive.com/financial-stock-info/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Kumar Raja Ph.D.",
     "house": "Brookline Capital Markets",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.unicycive.com/financial-stock-info/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Vamil Divan, M.D.",
     "house": "Guggenheim Securities",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.unicycive.com/financial-stock-info/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Swayampakula Ramakanth, Ph.D.",
     "house": "H.C. Wainwright",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.unicycive.com/financial-stock-info/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Elemer Piros, Ph.D.",
     "house": "Lucid Capital Markets",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.unicycive.com/financial-stock-info/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Jason McCarthy, Ph.D.",
     "house": "Maxim Group",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.unicycive.com/financial-stock-info/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Robert LeBoyer",
     "house": "Noble Life Science Partners",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.unicycive.com/financial-stock-info/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Yasmeen Rahimi, Ph.D.",
     "house": "Piper Sandler",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.unicycive.com/financial-stock-info/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Bruce Jackson",
     "house": "The Benchmark Company, LLC",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.unicycive.com/financial-stock-info/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Ed Arce",
     "house": "WestPark Capital",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.unicycive.com/financial-stock-info/analyst-coverage",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://ir.unicycive.com/financial-stock-info/analyst-coverage",
     "result": "read: 10 of 20 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "agm_egm": 4,
    "corporate_news": 4,
    "director_change": 2,
    "directors_dealings": 16,
    "prospectus": 2,
    "regulatory_filing": 20,
    "results": 8
   },
   "cadence_median_gap_days": 6,
   "filing_days": 30,
   "filings": 56,
   "latency_days": 10,
   "latest": [
    {
     "category": "4",
     "date": "2026-10-29",
     "source": "https://www.sec.gov/Archives/edgar/data/1766140/000121390026113840/xslF345X06/ownership.xml",
     "title": "4",
     "type": "directors_dealings"
    },
    {
     "category": "3",
     "date": "2026-10-01",
     "source": "https://www.sec.gov/Archives/edgar/data/1766140/000121390026105816/xslF345X06/ownership.xml",
     "title": "3",
     "type": "directors_dealings"
    },
    {
     "category": "8-K",
     "date": "2026-09-29",
     "source": "https://www.sec.gov/Archives/edgar/data/1766140/000121390026104314/ea0306967-8k_unicycive.htm",
     "title": "8-K — CURRENT REPORT (items 5.02,8.01,9.01)",
     "type": "director_change"
    },
    {
     "category": "8-K",
     "date": "2026-09-28",
     "source": "https://www.sec.gov/Archives/edgar/data/1766140/000121390026104076/ea0306890-8k_unicycive.htm",
     "title": "8-K — CURRENT REPORT (items 8.01)",
     "type": "corporate_news"
    },
    {
     "category": "SCHEDULE 13G/A",
     "date": "2026-08-14",
     "source": "https://www.sec.gov/Archives/edgar/data/1766140/000121390026090075/xslSCHEDULE_13G_X02/primary_doc.xml",
     "title": "SCHEDULE 13G/A",
     "type": "regulatory_filing"
    }
   ],
   "latest_filing_date": "2026-10-29",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/UNCY",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "read_by": "SEC Fails-to-Deliver data (CUSIP for the symbol) · ISIN = US + CUSIP + ISO 6166 check digit",
    "read_date": "2026-10-06",
    "read_date_basis": "last_seen",
    "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data",
    "state": "sourced",
    "value": "US90466Y2028"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001766140.json",
    "state": "sourced",
    "value": "United States — Delaware"
   },
   "lei": {
    "market": "US",
    "reason": "no GLEIF record with the exact legal name in jurisdiction US-DE",
    "state": "not_on_record"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001766140.json",
    "state": "sourced",
    "value": "Unicycive Therapeutics, Inc."
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001766140.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001766140.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "UNCY"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:77ca781f9f4b3b88fba0e33bd370a02c63c75e74a46a7a8ea4e26b44f873440b",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/UNCY",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:77ca781f9f4b3b88fba0e33bd370a02c63c75e74a46a7a8ea4e26b44f873440b",
 "path": "/us/NASDAQ/UNCY",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Unicycive Therapeutics, Inc., listed on NASDAQ under ticker UNCY. Its ISIN is US90466Y2028. Its LEI is not on the record (no GLEIF record with the exact legal name in jurisdiction US-DE). Its security type is Corporate, its segment is not on the record, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is United States, Delaware. Its listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 56 filings in the twelve months to 2026-11-08, across 30 filing days. The filings comprise 4 agm_egm, 4 corporate_news, 2 director_change, 16 directors_dealings, 2 prospectus, 20 regulatory_filing and 8 results. The median gap between filing days is 6 days. The latest filing is dated 2026-10-29 and is of type directors_dealings, 10 days before the record date. The exchange median for NASDAQ is 52 filings, a cadence gap of 6.0 days and a latency of 5.0 days across 4359 issuers. The sector median for 2834 Pharmaceutical Preparations is 63.0 filings, a cadence gap of 6.0 days and a latency of 4.0 days across 526 issuers.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is GRASSI & CO., CPAs, P.C., located in Jericho, New York. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting or name change lines. The domicile change is not on the record (EDGAR states no dated change of state of incorporation on a filing line). The segment move is not on the record (the exchanges' tier transfers are not EDGAR filings). The halt flag reads listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The issuer's own investor-relations page names 10 research houses: B. Riley, Brookline Capital Markets, Guggenheim Securities, H.C. Wainwright, Lucid Capital Markets, Maxim Group, Noble Life Science Partners, Piper Sandler, The Benchmark Company, LLC, and WestPark Capital.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The sealed years that hold the issuer are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12. The market's vintage is sealed.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "9 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001766140.json"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/UNCY"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the auditor",
   "source": "https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://ir.unicycive.com/financial-stock-info/analyst-coverage"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/UNCY"
  }
 ],
 "title": "Unicycive Therapeutics, Inc. (UNCY) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}